AstraZeneca and Oracle to find trial patients in real-world health data — Abu Dhabi is first up
The companies announced on Tuesday 20 October 2026 a collaboration to use artificial intelligence and real-world patient data for recruitment, earlier diagnosis and drug safety. The first project will find patients with uncontrolled high blood pressure in Abu Dhabi.
Pharmaceutical giant AstraZeneca and software company Oracle announced on Tuesday 20 October 2026 a collaboration in which artificial intelligence and real-world health data will be used to identify patients eligible for clinical trials and to monitor safety signals. According to Reuters, which relayed the companies' announcement, the collaboration will combine AstraZeneca's drug development expertise with Oracle's AI and health technology capacity.
The most immediately concrete element is not a local pilot project: the first program will support hypertension research in Abu Dhabi, in partnership with the Emirati health company M42.
What the collaboration actually covers
The initiative differs from many other pharma–AI deals by not being about drug discovery. According to the Wall Street Journal, citing AstraZeneca, it is instead about testing practical ways of connecting scientific research directly to clinical workflows. Three areas are specifically mentioned: recruitment to clinical trials, earlier diagnosis of serious diseases, and monitoring of drug safety (pharmacovigilance).
MarketScreener, which also relayed the announcement, describes four key areas: optimization of clinical trials, early diagnosis, pharmacovigilance and health data.
The collaboration encompasses several international projects in the U.S., the Middle East and Europe, spanning AstraZeneca's core areas: cancer, cardiovascular disease, kidney and metabolic disease, respiratory disease, immunology and rare diagnoses. According to the announcement, international rollout will be coordinated with local authorities and take place in compliance with local regulatory frameworks.
The first project: hypertension in Abu Dhabi
The Abu Dhabi program with M42 targets patients whose blood pressure is not under control. The goal, according to MarketScreener, is to help medical teams identify these patients, implement treatment guidelines, and at the same time streamline recruitment to clinical trials related to high blood pressure.
The model is worth noting: the program combines a clinical goal (better management of uncontrolled hypertension) with a research goal (finding and recruiting trial participants). Patient identification thus becomes both a health intervention and a recruitment channel – a design that could reduce the divide between routine care and trial participation.
Why recruitment is the bottleneck
Patient recruitment is regarded as one of the biggest challenges in clinical research. Delayed enrollment often extends trial timelines and increases development costs, Reuters writes as context. Recruitment failure is a classic cause of trials being delayed or abandoned, and a system that can find eligible patients in real-world health data addresses this bottleneck directly.
Part of a broader strategy
AstraZeneca has a public target of more than 80 billion dollars in annual revenue by 2030 and, according to Reuters, is working to expand its portfolio and resolve bottlenecks in drug development. The Oracle deal came shortly after another major AI agreement: last week the company announced a partnership with the startup Insitro to use artificial intelligence on cardiometabolic diseases, in a deal worth up to 1.5 billion dollars.
The deal is also part of a wave of similar pharma–AI collaborations. Earlier this year, Novo Nordisk made deals with the AI labs Anthropic and OpenAI, as well as Amazon.
What is not known
Several key details are missing from the public information. No financial terms for the Oracle collaboration have been disclosed, nor timelines for the international projects or which specific AI systems will be used. All that exists are the companies' own descriptions as relayed in secondary reporting from Reuters, the Wall Street Journal and MarketScreener – not a primary press release or documentation of results.
Open questions include how data sharing between AstraZeneca, Oracle and healthcare institutions in different jurisdictions will be handled, how coordination with local authorities will play out in practice, and whether the Abu Dhabi program will actually deliver measurable improvements in recruitment speed and blood pressure management. These questions cannot be answered on the basis of the announcement alone.